[Skip to Content]
[Skip to Content Landing]
JAMA Clinical Evidence Synopsis
December 11, 2018

Treatment of Lower Extremity Superficial Thrombophlebitis

Author Affiliations
  • 1Amsterdam Cardiovascular Sciences, University of Amsterdam, Amsterdam, the Netherlands
  • 2Department of Guideline Development and Science, Dutch College of General Practitioners, Utrecht, the Netherlands
JAMA. 2018;320(22):2367-2368. doi:10.1001/jama.2018.16623

Clinical Question  Which treatments for lower extremity superficial thrombophlebitis (ST) are associated with lower rates of venous thromboembolic events (VTEs) vs placebo?

Bottom Line  A dose of 2.5 mg of fondaparinux administered subcutaneously once daily for 45 days is associated with fewer cases of symptomatic VTE without an increase in major bleeding vs placebo. Low-molecular-weight heparin (LMWH) and nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with lower rates of ST extension or recurrence vs placebo, but data regarding symptomatic VTE remain inconclusive. Oral rivaroxaban requires further evaluation.